Greenwich LifeSciences (GLSI) said Wednesday that the European Medicines Agency has approved its application to add 11 new sites in Spain, Germany, and Poland for a late-stage trial of GLSI-100 to prevent breast cancer recurrences.
The company said that with the latest approval, regulators have cleared the way for the activation of 110 to 115 sites in Europe.
Greenwich said it plans to file applications with the EMA to add 5 to 10 additional sites in Ireland, Romania, and potentially other European countries.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。